Cargando…

A clinical guideline-based management of type 2 diabetes by ayurvedic practitioners in Nepal: A feasibility cluster randomized controlled trial protocol

Type 2 diabetes mellitus (T2DM) is a common chronic condition with significant health and socioeconomic consequences. In Nepal, T2DM is a common disease for which people consult ayurvedic (traditional medical system) practitioners and use ayurvedic medicines. Strong concerns remain about the subopti...

Descripción completa

Detalles Bibliográficos
Autores principales: Chattopadhyay, Kaushik, Dhimal, Meghnath, Karki, Shristi, Regmi, Prerok, Bista, Bihungum, Biswas, Tuhin Kanti, Heinrich, Michael, Panniyammakal, Jeemon, Tandon, Nikhil, Leonardi-Bee, Jo, Kinra, Sanjay, Greenfield, Sheila Margaret, Lewis, Sarah Anne, Upadhyay, Vasudev, Gyanwali, Pradip
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9704971/
https://www.ncbi.nlm.nih.gov/pubmed/36451377
http://dx.doi.org/10.1097/MD.0000000000031452
_version_ 1784840178135728128
author Chattopadhyay, Kaushik
Dhimal, Meghnath
Karki, Shristi
Regmi, Prerok
Bista, Bihungum
Biswas, Tuhin Kanti
Heinrich, Michael
Panniyammakal, Jeemon
Tandon, Nikhil
Leonardi-Bee, Jo
Kinra, Sanjay
Greenfield, Sheila Margaret
Lewis, Sarah Anne
Upadhyay, Vasudev
Gyanwali, Pradip
author_facet Chattopadhyay, Kaushik
Dhimal, Meghnath
Karki, Shristi
Regmi, Prerok
Bista, Bihungum
Biswas, Tuhin Kanti
Heinrich, Michael
Panniyammakal, Jeemon
Tandon, Nikhil
Leonardi-Bee, Jo
Kinra, Sanjay
Greenfield, Sheila Margaret
Lewis, Sarah Anne
Upadhyay, Vasudev
Gyanwali, Pradip
author_sort Chattopadhyay, Kaushik
collection PubMed
description Type 2 diabetes mellitus (T2DM) is a common chronic condition with significant health and socioeconomic consequences. In Nepal, T2DM is a common disease for which people consult ayurvedic (traditional medical system) practitioners and use ayurvedic medicines. Strong concerns remain about the suboptimal T2DM management of many patients by ayurvedic practitioners, and therefore, based on the best available scientific evidence, we have developed a clinical guideline for managing T2DM by ayurvedic practitioners. The research question to be addressed by a definitive cluster randomized controlled trial (RCT) is whether the introduction of a clinical guideline can improve the management of T2DM by ayurvedic practitioners in Nepal as compared to usual ayurvedic management (i.e., without any clinical guideline). In preparation for this future work, this current study aims to determine the feasibility of undertaking the definitive cluster RCT. METHODS: This is a 2-arm, feasibility cluster RCT with a blinded outcome assessment and a qualitative evaluation. The study is conducted in 12 public and private ayurveda centers in and outside the Kathmandu Valley in Nepal (1:1 intervention:control). Eligible participants should be new T2DM adult patients (i.e., treatment naïve) - the glycated hemoglobin level should be 6.5% or above but less than 9%. At least 120 participants (60/group) will be recruited and followed up for 6 months. Important parameters, needed to design the definitive trial, will be estimated, such as the standard deviation of the outcome measure (i.e., glycated hemoglobin level at 6-month follow-up), intraclass correlation coefficient, cluster size, recruitment, the time needed to recruit participants, follow-up, and adherence to the recommended ayurvedic medicine. Semi-structured qualitative interviews will be conducted with around 20 to 30 participants and all the participating ayurvedic practitioners to explore their experiences and perspectives of taking part in the study and of the intervention and a sample of eligible people declining to participate in the study to explore the reasons behind nonparticipation. DISCUSSION: We are now conducting a feasibility cluster RCT in Nepal to determine the feasibility of undertaking the definitive cluster trial. The first participant was recruited on 17 July 2022. If the feasibility is promising (such as recruitment, follow-up, and adherence to the recommended ayurvedic medicine), then the parameters estimated will be used to design the definitive cluster trial. Decisions over whether to modify the protocol will mainly be informed by the qualitative data.
format Online
Article
Text
id pubmed-9704971
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-97049712022-11-29 A clinical guideline-based management of type 2 diabetes by ayurvedic practitioners in Nepal: A feasibility cluster randomized controlled trial protocol Chattopadhyay, Kaushik Dhimal, Meghnath Karki, Shristi Regmi, Prerok Bista, Bihungum Biswas, Tuhin Kanti Heinrich, Michael Panniyammakal, Jeemon Tandon, Nikhil Leonardi-Bee, Jo Kinra, Sanjay Greenfield, Sheila Margaret Lewis, Sarah Anne Upadhyay, Vasudev Gyanwali, Pradip Medicine (Baltimore) 3800 Type 2 diabetes mellitus (T2DM) is a common chronic condition with significant health and socioeconomic consequences. In Nepal, T2DM is a common disease for which people consult ayurvedic (traditional medical system) practitioners and use ayurvedic medicines. Strong concerns remain about the suboptimal T2DM management of many patients by ayurvedic practitioners, and therefore, based on the best available scientific evidence, we have developed a clinical guideline for managing T2DM by ayurvedic practitioners. The research question to be addressed by a definitive cluster randomized controlled trial (RCT) is whether the introduction of a clinical guideline can improve the management of T2DM by ayurvedic practitioners in Nepal as compared to usual ayurvedic management (i.e., without any clinical guideline). In preparation for this future work, this current study aims to determine the feasibility of undertaking the definitive cluster RCT. METHODS: This is a 2-arm, feasibility cluster RCT with a blinded outcome assessment and a qualitative evaluation. The study is conducted in 12 public and private ayurveda centers in and outside the Kathmandu Valley in Nepal (1:1 intervention:control). Eligible participants should be new T2DM adult patients (i.e., treatment naïve) - the glycated hemoglobin level should be 6.5% or above but less than 9%. At least 120 participants (60/group) will be recruited and followed up for 6 months. Important parameters, needed to design the definitive trial, will be estimated, such as the standard deviation of the outcome measure (i.e., glycated hemoglobin level at 6-month follow-up), intraclass correlation coefficient, cluster size, recruitment, the time needed to recruit participants, follow-up, and adherence to the recommended ayurvedic medicine. Semi-structured qualitative interviews will be conducted with around 20 to 30 participants and all the participating ayurvedic practitioners to explore their experiences and perspectives of taking part in the study and of the intervention and a sample of eligible people declining to participate in the study to explore the reasons behind nonparticipation. DISCUSSION: We are now conducting a feasibility cluster RCT in Nepal to determine the feasibility of undertaking the definitive cluster trial. The first participant was recruited on 17 July 2022. If the feasibility is promising (such as recruitment, follow-up, and adherence to the recommended ayurvedic medicine), then the parameters estimated will be used to design the definitive cluster trial. Decisions over whether to modify the protocol will mainly be informed by the qualitative data. Lippincott Williams & Wilkins 2022-11-25 /pmc/articles/PMC9704971/ /pubmed/36451377 http://dx.doi.org/10.1097/MD.0000000000031452 Text en Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY) (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle 3800
Chattopadhyay, Kaushik
Dhimal, Meghnath
Karki, Shristi
Regmi, Prerok
Bista, Bihungum
Biswas, Tuhin Kanti
Heinrich, Michael
Panniyammakal, Jeemon
Tandon, Nikhil
Leonardi-Bee, Jo
Kinra, Sanjay
Greenfield, Sheila Margaret
Lewis, Sarah Anne
Upadhyay, Vasudev
Gyanwali, Pradip
A clinical guideline-based management of type 2 diabetes by ayurvedic practitioners in Nepal: A feasibility cluster randomized controlled trial protocol
title A clinical guideline-based management of type 2 diabetes by ayurvedic practitioners in Nepal: A feasibility cluster randomized controlled trial protocol
title_full A clinical guideline-based management of type 2 diabetes by ayurvedic practitioners in Nepal: A feasibility cluster randomized controlled trial protocol
title_fullStr A clinical guideline-based management of type 2 diabetes by ayurvedic practitioners in Nepal: A feasibility cluster randomized controlled trial protocol
title_full_unstemmed A clinical guideline-based management of type 2 diabetes by ayurvedic practitioners in Nepal: A feasibility cluster randomized controlled trial protocol
title_short A clinical guideline-based management of type 2 diabetes by ayurvedic practitioners in Nepal: A feasibility cluster randomized controlled trial protocol
title_sort clinical guideline-based management of type 2 diabetes by ayurvedic practitioners in nepal: a feasibility cluster randomized controlled trial protocol
topic 3800
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9704971/
https://www.ncbi.nlm.nih.gov/pubmed/36451377
http://dx.doi.org/10.1097/MD.0000000000031452
work_keys_str_mv AT chattopadhyaykaushik aclinicalguidelinebasedmanagementoftype2diabetesbyayurvedicpractitionersinnepalafeasibilityclusterrandomizedcontrolledtrialprotocol
AT dhimalmeghnath aclinicalguidelinebasedmanagementoftype2diabetesbyayurvedicpractitionersinnepalafeasibilityclusterrandomizedcontrolledtrialprotocol
AT karkishristi aclinicalguidelinebasedmanagementoftype2diabetesbyayurvedicpractitionersinnepalafeasibilityclusterrandomizedcontrolledtrialprotocol
AT regmiprerok aclinicalguidelinebasedmanagementoftype2diabetesbyayurvedicpractitionersinnepalafeasibilityclusterrandomizedcontrolledtrialprotocol
AT bistabihungum aclinicalguidelinebasedmanagementoftype2diabetesbyayurvedicpractitionersinnepalafeasibilityclusterrandomizedcontrolledtrialprotocol
AT biswastuhinkanti aclinicalguidelinebasedmanagementoftype2diabetesbyayurvedicpractitionersinnepalafeasibilityclusterrandomizedcontrolledtrialprotocol
AT heinrichmichael aclinicalguidelinebasedmanagementoftype2diabetesbyayurvedicpractitionersinnepalafeasibilityclusterrandomizedcontrolledtrialprotocol
AT panniyammakaljeemon aclinicalguidelinebasedmanagementoftype2diabetesbyayurvedicpractitionersinnepalafeasibilityclusterrandomizedcontrolledtrialprotocol
AT tandonnikhil aclinicalguidelinebasedmanagementoftype2diabetesbyayurvedicpractitionersinnepalafeasibilityclusterrandomizedcontrolledtrialprotocol
AT leonardibeejo aclinicalguidelinebasedmanagementoftype2diabetesbyayurvedicpractitionersinnepalafeasibilityclusterrandomizedcontrolledtrialprotocol
AT kinrasanjay aclinicalguidelinebasedmanagementoftype2diabetesbyayurvedicpractitionersinnepalafeasibilityclusterrandomizedcontrolledtrialprotocol
AT greenfieldsheilamargaret aclinicalguidelinebasedmanagementoftype2diabetesbyayurvedicpractitionersinnepalafeasibilityclusterrandomizedcontrolledtrialprotocol
AT lewissarahanne aclinicalguidelinebasedmanagementoftype2diabetesbyayurvedicpractitionersinnepalafeasibilityclusterrandomizedcontrolledtrialprotocol
AT upadhyayvasudev aclinicalguidelinebasedmanagementoftype2diabetesbyayurvedicpractitionersinnepalafeasibilityclusterrandomizedcontrolledtrialprotocol
AT gyanwalipradip aclinicalguidelinebasedmanagementoftype2diabetesbyayurvedicpractitionersinnepalafeasibilityclusterrandomizedcontrolledtrialprotocol
AT chattopadhyaykaushik clinicalguidelinebasedmanagementoftype2diabetesbyayurvedicpractitionersinnepalafeasibilityclusterrandomizedcontrolledtrialprotocol
AT dhimalmeghnath clinicalguidelinebasedmanagementoftype2diabetesbyayurvedicpractitionersinnepalafeasibilityclusterrandomizedcontrolledtrialprotocol
AT karkishristi clinicalguidelinebasedmanagementoftype2diabetesbyayurvedicpractitionersinnepalafeasibilityclusterrandomizedcontrolledtrialprotocol
AT regmiprerok clinicalguidelinebasedmanagementoftype2diabetesbyayurvedicpractitionersinnepalafeasibilityclusterrandomizedcontrolledtrialprotocol
AT bistabihungum clinicalguidelinebasedmanagementoftype2diabetesbyayurvedicpractitionersinnepalafeasibilityclusterrandomizedcontrolledtrialprotocol
AT biswastuhinkanti clinicalguidelinebasedmanagementoftype2diabetesbyayurvedicpractitionersinnepalafeasibilityclusterrandomizedcontrolledtrialprotocol
AT heinrichmichael clinicalguidelinebasedmanagementoftype2diabetesbyayurvedicpractitionersinnepalafeasibilityclusterrandomizedcontrolledtrialprotocol
AT panniyammakaljeemon clinicalguidelinebasedmanagementoftype2diabetesbyayurvedicpractitionersinnepalafeasibilityclusterrandomizedcontrolledtrialprotocol
AT tandonnikhil clinicalguidelinebasedmanagementoftype2diabetesbyayurvedicpractitionersinnepalafeasibilityclusterrandomizedcontrolledtrialprotocol
AT leonardibeejo clinicalguidelinebasedmanagementoftype2diabetesbyayurvedicpractitionersinnepalafeasibilityclusterrandomizedcontrolledtrialprotocol
AT kinrasanjay clinicalguidelinebasedmanagementoftype2diabetesbyayurvedicpractitionersinnepalafeasibilityclusterrandomizedcontrolledtrialprotocol
AT greenfieldsheilamargaret clinicalguidelinebasedmanagementoftype2diabetesbyayurvedicpractitionersinnepalafeasibilityclusterrandomizedcontrolledtrialprotocol
AT lewissarahanne clinicalguidelinebasedmanagementoftype2diabetesbyayurvedicpractitionersinnepalafeasibilityclusterrandomizedcontrolledtrialprotocol
AT upadhyayvasudev clinicalguidelinebasedmanagementoftype2diabetesbyayurvedicpractitionersinnepalafeasibilityclusterrandomizedcontrolledtrialprotocol
AT gyanwalipradip clinicalguidelinebasedmanagementoftype2diabetesbyayurvedicpractitionersinnepalafeasibilityclusterrandomizedcontrolledtrialprotocol